Discovery of Novel Dual-target Inhibitors of LSD1/EGFR for Non-small Cell Lung Cancer Therapy

Overview

Journal Acta Pharmacol Sin

Specialty Pharmacology

Date 2025 Jan 3

PMID 39753983

Authors

Yu Wei

Ming-Ming Sun

Rui-Li Zhang

Lin Wang

Li-Hong Yang

Chang-Liang Shan

Jian-Ping Lin

Affiliations

Soon will be listed here.

Abstract

Histone lysine-specific demethylase 1 (LSD1) is overexpressed in various solid and hematological tumors, suggesting its potential as a therapeutic target, but there are currently no LSD1 inhibitors available on the market. In this study we employed a computer-guided approach to identify novel LSD1/EGFR dual inhibitors as a potential therapeutic agent for non-small cell lung cancer. Through a multi-stage virtual screening approach, we found L-1 and L-6, two compounds with unique scaffolds that effectively inhibit LSD1 with IC values of 6.24 and 9.26 μM, respectively. Using molecular similarity-based screening, 48 analogs of L-1 and L-6 were retrieved from ChemDiv library, 18 analogs were selected for biological activity analysis. Eight compounds showed weaker inhibitory activity against LSD1, with IC values of 19.79 - 35.70 μM. Moreover, L-1, L-6, and two analogs of L-6 (D-14 and D-16) were found to inhibit triple-mutant EGFR (L858R/T790M/C797S) with potencies ranging from 5.01 to 86.70 μM, and to inhibit double-mutant EGFR (T790M/L858R) with potencies ranging from 2.06 to 64.36 μM. In BaF3 cells that stably express EGFR (L858R/T790M/C797S), the inhibitory activity of L-1, L-6, D-14 and D-16 ranged from 2.72 to 8.99 μM. L-1 that shows the highest biological activity across BaF3 cell, mutant EGFR kinase and LSD1 assays due to its dual targeting of LSD1/EGFR, emerges as a promising lead compound for non-small cell lung cancer treatment. This study demonstrates that L-1 efficiently inhibits lung cancer growth in vitro and in vivo, suggesting it as a potential lead for non-small cell lung cancer treatment, highlighting the utility of virtual screening methods in discovering multi-target inhibitors and strategies for other diseases.

References

Shi Y, Lan F, Matson C, Mulligan P, Whetstine J, Cole P . Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004; 119(7):941-53. DOI: 10.1016/j.cell.2004.12.012. View

Lv T, Yuan D, Miao X, Lv Y, Zhan P, Shen X . Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer. PLoS One. 2012; 7(4):e35065. PMC: 3320866. DOI: 10.1371/journal.pone.0035065. View

Mohammad H, Smitheman K, Kamat C, Soong D, Federowicz K, Van Aller G . A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. 2015; 28(1):57-69. DOI: 10.1016/j.ccell.2015.06.002. View

Sehrawat A, Gao L, Wang Y, Bankhead 3rd A, McWeeney S, King C . LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018; 115(18):E4179-E4188. PMC: 5939079. DOI: 10.1073/pnas.1719168115. View

Metzger E, Wissmann M, Yin N, Muller J, Schneider R, Peters A . LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature. 2005; 437(7057):436-9. DOI: 10.1038/nature04020. View

Li Y, Tian X, Sui C, Jiang Y, Liu Y, Meng F . Interference of lysine-specific demethylase 1 inhibits cellular invasion and proliferation in vivo in gastric cancer MKN-28 cells. Biomed Pharmacother. 2016; 82:498-508. DOI: 10.1016/j.biopha.2016.04.070. View

Huang M, Hou J, Wang Y, Xie M, Wei C, Nie F . Long Noncoding RNA LINC00673 Is Activated by SP1 and Exerts Oncogenic Properties by Interacting with LSD1 and EZH2 in Gastric Cancer. Mol Ther. 2017; 25(4):1014-1026. PMC: 5383578. DOI: 10.1016/j.ymthe.2017.01.017. View

Lan W, Zhang D, Jiang J . The roles of LSD1-mediated epigenetic modifications in maintaining the pluripotency of bladder cancer stem cells. Med Hypotheses. 2013; 81(5):823-5. DOI: 10.1016/j.mehy.2013.09.005. View

Kosumi K, Baba Y, Sakamoto A, Ishimoto T, Harada K, Nakamura K . Lysine-specific demethylase-1 contributes to malignant behavior by regulation of invasive activity and metabolic shift in esophageal cancer. Int J Cancer. 2015; 138(2):428-39. DOI: 10.1002/ijc.29714. View

10.

Callegari K, Maegawa S, Bravo-Alegria J, Gopalakrishnan V . Pharmacological inhibition of LSD1 activity blocks REST-dependent medulloblastoma cell migration. Cell Commun Signal. 2018; 16(1):60. PMC: 6145331. DOI: 10.1186/s12964-018-0275-5. View

11.

Lee C, Rudneva V, Erkek S, Zapatka M, Chau L, Tacheva-Grigorova S . Lsd1 as a therapeutic target in Gfi1-activated medulloblastoma. Nat Commun. 2019; 10(1):332. PMC: 6338772. DOI: 10.1038/s41467-018-08269-5. View

12.

Yi L, Cui Y, Xu Q, Jiang Y . Stabilization of LSD1 by deubiquitinating enzyme USP7 promotes glioblastoma cell tumorigenesis and metastasis through suppression of the p53 signaling pathway. Oncol Rep. 2016; 36(5):2935-2945. DOI: 10.3892/or.2016.5099. View

13.

Kozono D, Li J, Nitta M, Sampetrean O, Gonda D, Kushwaha D . Dynamic epigenetic regulation of glioblastoma tumorigenicity through LSD1 modulation of MYC expression. Proc Natl Acad Sci U S A. 2015; 112(30):E4055-64. PMC: 4522819. DOI: 10.1073/pnas.1501967112. View

14.

Lim S, Janzer A, Becker A, Zimmer A, Schule R, Buettner R . Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis. 2010; 31(3):512-20. DOI: 10.1093/carcin/bgp324. View

15.

Wang Y, Zhang H, Chen Y, Sun Y, Yang F, Yu W . LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell. 2009; 138(4):660-72. DOI: 10.1016/j.cell.2009.05.050. View

16.

Hino S, Kohrogi K, Nakao M . Histone demethylase LSD1 controls the phenotypic plasticity of cancer cells. Cancer Sci. 2016; 107(9):1187-92. PMC: 5021031. DOI: 10.1111/cas.13004. View

17.

Schenk T, Chen W, Gollner S, Howell L, Jin L, Hebestreit K . Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med. 2012; 18(4):605-11. PMC: 3539284. DOI: 10.1038/nm.2661. View

18.

Fang J, Ying H, Mao T, Fang Y, Lu Y, Wang H . Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells. Oncotarget. 2017; 8(49):85085-85101. PMC: 5689595. DOI: 10.18632/oncotarget.18564. View

19.

Maiques-Diaz A, Spencer G, Lynch J, Ciceri F, Williams E, Amaral F . Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia. Cell Rep. 2018; 22(13):3641-3659. PMC: 5896174. DOI: 10.1016/j.celrep.2018.03.012. View

20.

Chen Y, Yang Y, Wang F, Wan K, Yamane K, Zhang Y . Crystal structure of human histone lysine-specific demethylase 1 (LSD1). Proc Natl Acad Sci U S A. 2006; 103(38):13956-61. PMC: 1599895. DOI: 10.1073/pnas.0606381103. View